1-(4-Methylpiperazin-1-yl)-2-naphthalen-2-ylethanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(4-Methylpiperazin-1-yl)-2-naphthalen-2-ylethanone
• 化学式: C₁₇H₂₀N₂O
• 分子量: 268.35
• InChiKey: OCZOKNBETBHNQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED UREA EIF2α KINASE ACTIVATORS<br/>[FR] ACTIVATEURS SUBSTITUÉS DE L'URÉE-KINASE EIF2&Agr;
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2015038778A1

  公开（公告）日：2015-03-19

  This disclosure relates to substituted urea eIF2α kinase activators including methods of making and using the same. For example, such activators can include cycloalkyl aryl ureas, which activate at least one eIF2α kinase. These compounds may be useful for treatment of diseases such as, for example, cancer, hemolytic anemia not caused by infectious agents, Wolcott-Rallison syndrome, neurodegenerative disease, tuberous sclerosis complex, fragile-X syndrome, autism spectrum disorder, and ribosomal defect disease.

  本公开涉及替代脲eIF2α激酶激活剂，包括其制备和使用方法。例如，这些激活剂可以包括环烷基芳基脲，其激活至少一种eIF2α激酶。这些化合物可能对治疗疾病有用，例如癌症、非感染性溶血性贫血、沃尔科特-拉里森综合征、神经退行性疾病、结节性硬化症、脆性X综合征、自闭症谱系障碍和核糖体缺陷疾病。
• [EN] SEROTONIN LIGANDS AS PRO-ERECTILE COMPOUNDS<br/>[FR] LIGANDS DE SEROTONINE EN TANT QUE COMPOSES FAVORISANT L'ERECTION
  申请人：NORTRAN PHARMACEUTICALS INC

  公开号：WO2000028993A1

  公开（公告）日：2000-05-25

  Compounds, and compositions including the compounds, are effective to treat or prevent sexual dysfunction, (by, for example, providing a pro-erectile function), when those compounds display selective serotonin (5HT) receptor activity. In one aspect, the compound is a 5HT2c agonist and a 5HT2a antagonist. In another aspect, the compound is a 5HT2c agonist, a 5HT2a antagonist, and a 5HT1a agonist (weak).

  化合物和包含这些化合物的组合物，在表现出选择性血清素（5HT）受体活性时，对于治疗或预防性功能障碍（例如，提供勃起功能）是有效的。在一个方面，该化合物是5HT2c激动剂和5HT2a拮抗剂。在另一个方面，该化合物是5HT2c激动剂，5HT2a拮抗剂和5HT1a激动剂（弱）。
• Substituted Urea eIF2alpha Kinase Activators
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20160318856A1

  公开（公告）日：2016-11-03

  This disclosure relates to substituted urea eIF2α kinase activators including methods of making and using the same. For example, such activators can include cycloalkyl aryl ureas, which activate at least one eIF2α kinase. These compounds may be useful for treatment of diseases such as, for example, cancer, hemolytic anemia not caused by infectious agents, Wolcott-Rallison syndrome, neurodegenerative disease, tuberous sclerosis complex, fragile-X syndrome, autism spectrum disorder, and ribosomal defect disease.